| Nuclear Receptor Subfamily 1 Group H Member 3 (LXR-α) | |
|---|---|
| Gene Symbol | NR1H3 |
| Full Name | Nuclear Receptor Subfamily 1 Group H Member 3 |
| Aliases | LXRα, LXRA, NR1H3, RLR |
| Chromosome | 11p11.2 |
| NCBI Gene ID | [10062](https://www.ncbi.nlm.nih.gov/gene/10062) |
| OMIM | [603711](https://www.omim.org/entry/603711) |
| Ensembl ID | ENSG00000125448 |
| UniProt ID | [Q9GZN5](https://www.uniprot.org/uniprot/Q9GZN5) |
| Protein Class | Nuclear receptor, ligand-activated transcription factor |
| Associated Diseases | [Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), [Atherosclerosis](/diseases/atherosclerosis), Multiple Sclerosis |
NR1H3 (Nuclear Receptor Subfamily 1 Group H Member 3), also known as LXRα (Liver X Receptor alpha), is a ligand-activated transcription factor that plays a critical role in regulating cholesterol homeostasis, lipid metabolism, and inflammatory responses[1]. Located on chromosome 11p11.2, this gene encodes a protein that is expressed in multiple tissues including the brain, liver, kidney, and adipose tissue[2].
The LXRα protein functions as a master regulator of cholesterol efflux, controlling the expression of genes involved in reverse cholesterol transport and protecting cells from cholesterol toxicity[3]. In the central nervous system, LXRα is expressed in neurons, astrocytes, and microglia, where it regulates cholesterol metabolism, neuroinflammation, and cellular survival pathways[4]. Dysregulation of NR1H3 has been implicated in the pathogenesis of both Alzheimer's disease (AD) and Parkinson's disease (PD)[5][6].
The NR1H3 gene spans approximately 21 kb and consists of 11 exons encoding a 445-amino acid protein. The LXRα protein contains several functional domains:
LXRα is activated by endogenous oxysterols, including 22(R)-hydroxycholesterol, 24(S)-hydroxycholesterol, and 27-hydroxycholesterol[7]. These cholesterol derivatives serve as physiological ligands that induce conformational changes, allowing recruitment of coactivators and transcriptional activation. Synthetic LXR agonists (e.g., T0901317, GW3965) have been developed for research and therapeutic applications, though they produce side effects including hypertriglyceridemia and hepatic steatosis.
The brain contains approximately 25% of the body's cholesterol, which is essential for synaptic plasticity, myelin formation, and neuronal membrane integrity. Neurons synthesize cholesterol locally, and this process is tightly regulated by LXRα[8]. Key target genes include:
Through activation of these genes, LXRα promotes cholesterol efflux from neurons and facilitates its transport to astrocytes for recycling[9]. This process is critical for maintaining neuronal cholesterol homeostasis and preventing cholesterol accumulation associated with neurodegeneration.
LXRα plays a crucial role in maintaining blood-brain barrier (BBB) function. Activation of LXRα suppresses SNAI2 (Snail family transcription repressor 2), which otherwise promotes BBB dysfunction[10]. This finding demonstrates that LXRα signaling is essential for BBB integrity, and its dysregulation may contribute to increased permeability and neuroinflammation in neurodegenerative diseases.
LXRα has potent anti-inflammatory effects in the brain. In microglia, LXR activation suppresses the expression of pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6[11]. This occurs through transrepression of NF-κB and AP-1 signaling pathways. Given that chronic neuroinflammation is a hallmark of both AD and PD, LXRα represents a potential therapeutic target for modulating neuroinflammatory responses.
LXRα regulates autophagy, a cellular process critical for clearing misfolded proteins and damaged organelles[12]. In neurodegenerative diseases, impaired autophagy leads to accumulation of amyloid-beta plaques and alpha-synuclein inclusions. LXR activation enhances autophagy flux, potentially facilitating clearance of these toxic protein aggregates.
In Alzheimer's disease, LXRα activation promotes clearance of amyloid-beta through upregulation of cholesterol efflux genes[13]. ABCA1 and ABCG1 enhance apolipoprotein-mediated Aβ clearance, reducing amyloid burden in mouse models. Studies in APP/PS1 transgenic mice show that LXR agonist treatment reduces soluble Aβ levels and improves cognitive performance[14].
LXR activation also affects tau pathology. In tauopathy models, LXR agonists reduce tau phosphorylation and aggregation[15]. This may occur through improved cholesterol homeostasis and reduced neuroinflammation, both of which contribute to tau pathogenesis.
Studies demonstrate that LXRα regulates age-related cognitive decline[16]. Genetic deletion of NR1H3 in mice leads to cognitive deficits, while LXR agonist treatment improves memory in aged mice. These effects are mediated through changes in synaptic plasticity, cholesterol metabolism, and neuroinflammation.
LXRα directly regulates APOE expression in the brain[17]. APOE4, the major genetic risk factor for AD, shows impaired lipid transport function. LXR activation increases APOE expression and improves lipid homeostasis, potentially counteracting APOE4-associated deficits. Genetic variants in NR1H3 have been associated with AD risk, highlighting the importance of this gene in disease pathogenesis[18].
In Parkinson's disease, LXR activation protects dopaminergic neurons from oxidative stress and cell death[19]. Studies using MPTP and 6-OHDA models show that LXR agonists prevent dopaminergic neuron loss and improve motor function. This neuroprotection involves reduced oxidative stress, improved mitochondrial function, and decreased neuroinflammation.
LXRα regulates mitochondrial function in dopaminergic neurons[20]. Activation of LXR improves mitochondrial respiration, reduces reactive oxygen species (ROS) production, and protects against mitochondrial toxins. This is particularly relevant to PD, where mitochondrial dysfunction is a central pathological feature.
LXR activation may affect alpha-synuclein aggregation, the hallmark protein inclusion in PD. Through enhanced autophagy and cholesterol homeostasis, LXR signaling may reduce alpha-synuclein toxicity. However, this relationship requires further investigation.
Given the prominent role of neuroinflammation in PD pathogenesis, LXR's anti-inflammatory properties are highly relevant[21]. LXR activation in microglia suppresses pro-inflammatory responses that contribute to dopaminergic neuron loss. This anti-inflammatory effect may be particularly important in PD progression.
Several LXR agonists have been explored in clinical trials for metabolic diseases, with potential applications in neurodegeneration[22]. However, side effects including elevated triglycerides and hepatic steatosis have limited clinical development. Newer, tissue-selective LXR modulators are being developed to separate beneficial CNS effects from peripheral metabolic side effects.
LXR modulation may be combined with other therapeutic approaches:
Key challenges include:
NR1H3 is expressed throughout the brain, with highest expression in:
LXRα interacts with various coregulators:
LXRα cross-talks with several other nuclear receptor pathways:
NR1H3 knockout mice exhibit:
Transgenic mice expressing human NR1H3 show: